pharmaphorum

JUNE 22, 2021

The US-based trial will enrol up to 280 participants aged 18 to 49 and will evaluate the safety of the mRNA vaccine candidate given at several dose levels, as well as its ability to stimulate an immune response against H3N2. billion, including $450 million of milestones from the original 2018 agreement.

Vaccines 114

Vaccines Immunity Immunization 114

Pharmaceutical Technology

OCTOBER 14, 2022

They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018. The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

Express Pharma

AUGUST 31, 2023

CanSino begun researching mRNA technology in 2018 and has built a facility in Shanghai that can produce up to 200 million doses a year, giving it the capacity to provide similar services to other companies, CanSino’s CEO and co-founder Xuefeng Yu told a news agency in an interview.

Vaccines 114

Vaccines Immunity Immunization 114

LifeProNow

APRIL 11, 2023

Under the updated arrangements, Sobi has entered into a direct relationship with Sanofi, replacing the previous participation agreement with AstraZeneca entered into in November 2018. In November 2022, Beyfortus was approved by the European Commission and by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Immunity 130

Immunity Immunization 130

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. The deal marks 10-year-old Moderna’s first acquisition.

Vaccines 97

Vaccines Immunity Immunization 97

European Pharmaceutical Review

APRIL 27, 2023

Monoclonal antibody ( mAb ) blinatumomab binds to leukaemia cells on one side and to immune cells on the other side. This connects the immune cells to the leukaemia cells and clears them up. Between 2018 and 2021, 30 children in nine countries were treated with blinatumomab.

Chemotherapy 105

Chemotherapy Immunity Immunization 105

pharmaphorum

MARCH 9, 2021

SARS-CoV-2 is likely to stay endemic in the human population for the foreseeable future, ExeVir noted, with variants capable of evading immunity the most likely cause of the disease in the future as global vaccination programmes begin to take effect. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Immunity 98

Immunity Immunization Vaccines 98

European Pharmaceutical Review

JANUARY 26, 2023

Through the Cancer Drugs Fund (CDF), in 2018, England was the first European country to provide access to a CAR T-cell therapy to treat these blood cancers. CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy 124

Chemotherapy Immunity Immunization 124

European Pharmaceutical Review

SEPTEMBER 29, 2023

Rybrevant and lazertinib Rybrevant is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity. The Phase III clinical trial demonstrated significant improvement in progression-free survival (PFS) in patients receiving Rybrevant with lazertinib compared to osimertinib.

Pharmaceutical Companies 111

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunity 111

Express Pharma

JUNE 26, 2024

The mRNA portion of these vaccines encodes a disease-specific antigen, prompting cells to display the antigen and stimulating an immune response. Jasper Morley, Pharma Analyst at GlobalData, comments: “Since the first FDA review designation for an mRNA vaccine in 2018, a total of 25 have been awarded.

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

JANUARY 26, 2021

Under the leadership of CEO Vas Narasimhan, who took over in 2018, the company has focused on using digital technology to engage with both patients and doctors. Sales of spinal muscular atrophy gene therapy Zolgensma have been hit because it requires a course of drugs to suppress the immune system before prescription.

Hospitals 111

Hospitals Immunity Immunization 111

pharmaphorum

JUNE 11, 2021

takeover of Bioverativ in 2018, is designed to block the complement pathway of the immune response, which becomes activated in CAD. In some cases patients can develop life-threatening blood clotting complications. Sutimlimab, which Sanofi acquired via its $11.6

Immunity 96

Immunity Immunization Labelling 96

pharmaphorum

FEBRUARY 3, 2021

The emergence of novel base editing technologies that do not generate double-strand breaks (DSBs) offer a promising and safer alternative to fine-tune the next generation of immune cell therapies, especially as our need to perform complex multi-gene alterations increases. Another area for potential improvement is the source of immune cells.

Immunity 98

Immunity Immunization Vaccines 98

Pharmaceutical Technology

JANUARY 23, 2023

The management of SLE and LN consists largely of treatment options that are based on highly efficacious steroids or immune-suppressive therapy with an undesirable safety profile, which includes accrued organ damage, infections and cancer. in 2018 across the 7MM despite being an off-label therapy for lupus.

Labelling 111

Labelling Immunity Immunization 111

Express Pharma

APRIL 24, 2023

Adults above 50 years of age and those suffering from chronic conditions such as diabetes, heart disease and kidney diseases are at an increased risk of developing shingles because of weakened immunity. The European Commission gave Shingrix approval for the prevention of shingles in adults 50 years of age or older in 2018.

Vaccines 97

Vaccines Diabetes Immunity Immunization 97

European Pharmaceutical Review

DECEMBER 22, 2022

These hurdles prevent intact therapeutic mRNAs from accumulating in the body or intended tissue and often trigger an immune response. The first drug to be approved with an ionised lipid was Onpattro® (patisiran) for the treatment of hereditary transthyretin protein amyloidosis in 2018. evade endolysosomal degradation .

Immunity 116

Immunity Immunization Vaccines Hospitals 116

pharmaphorum

JULY 9, 2021

London, UK-based Orchard bought the gene therapy from GSK in 2018 along with rights to Strimvelis, a gene therapy for the immune deficiency caused by the rare disease adenosine deaminase deficiency (ADA-SCID), which also came out of that collaboration.

Compounding 105

Compounding Immunity Immunization 105

pharmaphorum

DECEMBER 14, 2022

The vaccine primes the immune system to attack the tumour cells, while Keytruda blocks an immunological ‘brake’ that protects the cancer. In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

SEPTEMBER 6, 2022

The Nijmegen, Netherlands-based biotech was founded in 2018 to develop therapies designed to change the balance of protein expression within the tumour ‘microenvironment’, which can defend cancers against the immune system, and is increasingly becoming a source of new targets in oncology.

Chemotherapy 103

Chemotherapy Immunity Immunization 103

Express Pharma

JUNE 17, 2024

pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA). “This indication for the prevention of pneumonia caused by S.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

MAY 30, 2022

For comparison, there were just seven cases of monkeypox in the UK between 2018 and 2021, according to a just-published paper in The Lancet Infectious Diseases. No deaths have been reported from the infections.

Vaccines 105

Vaccines Labelling Immunity Immunization 105

pharmaphorum

DECEMBER 22, 2021

CFI regulates the activity of the complement immune system which is over-activated in GA. The one-shot therapy aims to treat GA by delivering the gene for complement factor I (CFI) to the eye using an adeno-associated virus (AAV) vector. It has been fast-tracked by the FDA.

Immunity 105

Immunity Immunization 105

Pharmaceutical Technology

JUNE 29, 2022

It merges a glycoprotein E antigen and an adjuvant system, AS01B, to induce a VZV-specific immune response that can aid in overcoming VZV immunity decline as people age. The Japanese MHLW granted initial approval for the vaccine in 2018 to prevent shingles in adults of the age 50 years and above.

Vaccines 64

Vaccines Immunity Immunization 64

Pharma Mirror

FEBRUARY 11, 2021

In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). Samsung Biologics (KRX: 207940.KS) We are extremely glad to.

Immunity 52

Immunity Immunization Drug Development 52

pharmaphorum

JANUARY 26, 2023

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. In 2018, England was the first country in Europe to provide access to a CAR-T cell therapy to treat these blood cancers, enabled via the Cancer Drugs Fund (CDF).

Chemotherapy 96

Chemotherapy Immunity Immunization Hospitals 96

pharmaphorum

JUNE 3, 2021

Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million. “Creating bispecific ISACs turbo-charged with potent immune stimulants is a novel concept that has tremendous potential for patients,” he added.

Immunity 52

Immunity Immunization 52

pharmaphorum

JANUARY 19, 2023

The HD-MAP utilises an ultra-high-density array of projections – which are invisible to the naked human eye – applied to the skin to rapidly deliver a vaccine to immune cells immediately below the skin’s surface. In February 2022, the UK said it would pledge £160 million to CEPI to speed up vaccine development.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

SEPTEMBER 25, 2020

DKN-01 is an antibody drug targeting the Dickkopf-1 (DKK1) protein, which is overexpressed in some forms of G/GEJ adenocarcinoma and is thought to be involved in tumour growth as well as dampening down the immune response against the cancer. The post FDA fast-tracks Leap’s gastric cancer immunotherapy appeared first on.

Immunity 72

Immunity Immunization Chemotherapy Hospitals 72

pharmaphorum

JUNE 7, 2021

.” J&J paid Argenx a hefty $300 million upfront to secure rights to cusatuzumab (also known as JNJ-4550) in December 2018, and also made a $200 million equity investment in the Belgian company as part of a deal that had a total value of $1.6

Chemotherapy 64

Chemotherapy Immunity Immunization 64

Pharmaceutical Business Review

JANUARY 2, 2025

BRII-179 is designed to elicit strong B-cell and T-cell immunity by expressing Pre-S1, Pre-S2, and S HBV surface antigens. Brii Bio originally licensed BRII-179 from VBI Vaccines in December 2018 and has since expanded its exclusive license to global rights as of July 2023. This study is currently fully enrolled.

Vaccines 59

Vaccines Immunity Immunization 59

pharmaphorum

MARCH 31, 2021

FAP is found in particular on the “stroma” of a tumour, an ecosystem of connective tissue and various non-malignant cell types like blood and immune cells that is thought to be involved in the origin and spread of cancers. In 2018 it paid $2.1 billion.

Immunity 98

Immunity Immunization Hospitals 98

The Thyroid Pharmacist

JUNE 30, 2023

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

Compounding 98

Compounding Immunity Immunization Compounding Pharmacies 98

pharmaphorum

JANUARY 19, 2021

In 2018, Pfizer’s ALK and ROS1 inhibitor Xalkori (crizotinib) was cleared by NICE in England – via the Cancer Drugs Fund (CDF) – as well as in Scotland by the SMC as a first-line option for treating ROS1-positive advanced NSCLC in adults. NICE is due to deliver a verdict on this use for the drug in April.

Chemotherapy 98

Chemotherapy Immunity Immunization 98

Pharmaceutical Business Review

JULY 21, 2023

It is shown that by using a further adjuvant, two doses administered over 14 days demonstrate protective levels of immune response, and this can be particularly significant in response to a public health emergency involving anthrax. In 2019, the US government commenced procuring this product for national preparedness efforts.

Vaccines 52

Vaccines Immunity Immunization Packaging 52

pharmaphorum

DECEMBER 21, 2020

Together the pair had managed to find a way to get the human body to accept strands of mRNA without an immune reaction, by tinkering with the chemical make-up of the molecule. This changed in 2018 when Moderna went public with what was at that time the largest IPO in biotech history.

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

JANUARY 10, 2022

Further than that, the company has been invested and involved in the area for a few years, after its partnership with BioNTech was agreed back in 2018. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

SEPTEMBER 2, 2020

Vopratelimab is a monoclonal antibody that binds to and activates the Inducible T Cell CO-Stimulator (ICOS), a protein on the surface of certain T cells that is believed to stimulate an immune response against a patient’s cancer.

Immunity 71

Immunity Immunization 71